Glenmede Trust Co. NA reduced its holdings in shares of Danaher Co. (NYSE:DHR) by 7.5% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 52,496 shares of the conglomerate’s stock after selling 4,286 shares during the period. Glenmede Trust Co. NA’s holdings in Danaher were worth $4,871,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. BlackRock Inc. raised its position in Danaher by 4.6% during the 4th quarter. BlackRock Inc. now owns 40,984,366 shares of the conglomerate’s stock valued at $3,804,169,000 after purchasing an additional 1,789,474 shares in the last quarter. Flossbach Von Storch AG raised its position in Danaher by 17.2% during the 3rd quarter. Flossbach Von Storch AG now owns 6,776,921 shares of the conglomerate’s stock valued at $581,324,000 after purchasing an additional 994,902 shares in the last quarter. Geode Capital Management LLC raised its position in Danaher by 2.7% during the 4th quarter. Geode Capital Management LLC now owns 6,263,971 shares of the conglomerate’s stock valued at $580,150,000 after purchasing an additional 167,442 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Danaher by 1.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 4,630,035 shares of the conglomerate’s stock valued at $397,144,000 after purchasing an additional 63,327 shares in the last quarter. Finally, Aristotle Capital Management LLC raised its position in Danaher by 5.4% during the 4th quarter. Aristotle Capital Management LLC now owns 4,301,473 shares of the conglomerate’s stock valued at $399,263,000 after purchasing an additional 222,067 shares in the last quarter. 77.64% of the stock is owned by hedge funds and other institutional investors.
In related news, EVP William K. Daniel sold 131,066 shares of the business’s stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $102.05, for a total transaction of $13,375,285.30. Following the transaction, the executive vice president now directly owns 270,523 shares in the company, valued at approximately $27,606,872.15. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Daniel L. Comas sold 62,989 shares of the business’s stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $101.96, for a total value of $6,422,358.44. Following the transaction, the chief financial officer now owns 227,805 shares in the company, valued at $23,226,997.80. The disclosure for this sale can be found here. Insiders sold a total of 313,260 shares of company stock worth $31,657,786 over the last quarter. Company insiders own 12.20% of the company’s stock.
DHR stock opened at $95.94 on Friday. Danaher Co. has a fifty-two week low of $78.97 and a fifty-two week high of $104.82. The stock has a market capitalization of $68,006.05, a price-to-earnings ratio of 24.19, a PEG ratio of 2.05 and a beta of 1.03. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.43 and a quick ratio of 1.05.
Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $1.19 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.16 by $0.03. Danaher had a return on equity of 11.36% and a net margin of 13.60%. The business had revenue of $5.09 billion for the quarter, compared to the consensus estimate of $4.97 billion. During the same period last year, the business posted $1.05 EPS. The business’s revenue was up 10.9% compared to the same quarter last year. sell-side analysts anticipate that Danaher Co. will post 4.38 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, April 27th. Stockholders of record on Thursday, March 29th will be issued a $0.16 dividend. The ex-dividend date is Wednesday, March 28th. This is an increase from Danaher’s previous quarterly dividend of $0.14. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.67%. Danaher’s dividend payout ratio (DPR) is currently 15.86%.
A number of equities research analysts have weighed in on the company. Credit Suisse Group lifted their target price on Danaher from $99.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. Zacks Investment Research raised Danaher from a “hold” rating to a “buy” rating and set a $112.00 target price for the company in a research report on Thursday. Stifel Nicolaus lifted their target price on Danaher from $110.00 to $115.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Robert W. Baird reaffirmed a “buy” rating on shares of Danaher in a research report on Friday, January 12th. Finally, UBS assumed coverage on Danaher in a research report on Monday, January 22nd. They set a “buy” rating and a $99.97 target price for the company. One research analyst has rated the stock with a sell rating, four have issued a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $102.23.
TRADEMARK VIOLATION NOTICE: This story was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.thelincolnianonline.com/2018/03/24/danaher-co-dhr-shares-sold-by-glenmede-trust-co-na.html.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors.
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.